DIGITAL BREAST TOMOSYNTHESIS EQUIPMENT MARKET ANALYSIS

Market Challenges And Opportunities

Global Digital Breast Tomosynthesis Equipment Market – Driver

Technological advancements and increasing incidence of breast cancer

The market is expanding due to technological developments in digital breast tomosynthesis equipment. Manufacturers are putting their efforts into creating cutting-edge technology, which is enhancing the effectiveness of breast cancer diagnosis and treatment. Examples of this equipment include automated breast ultrasonography systems and biopsy devices. For instance, in December 2022, MedCognetics, Inc., an advanced AI software platform announced it had received U.S Food and Drug Administration (FDA) 510(k) clearance of its artificial intelligence (AI)-enabled software for breast cancer screening, QmTRIAGE. The Company is developing the next generation of AI medical imaging technology with an initial focus on improving outcomes of early breast cancer detection, particularly across a diverse group of patients, as well as helping radiologists with unmanageable caseloads.

Growing awareness about breast cancer screening

Delayed in the breast cancer screening due to pandemic led to a decrease in the breast cancer screening which result’s to a growth in breast cancer after early stages.

For instance, in August 2020, Hologic, Inc., an innovative medical technology company, launched the Back to screening campaign encouraging women to schedule their annual mammograms now that healthcare facilities across the nation are re-opening their doors following closures due to the COVID-19 pandemic.

Global Digital Breast Tomosynthesis Equipment Market: Restraint

Limited reimbursement policies for breast tomosynthesis and Lack of awareness about the benefits of digital breast tomosynthesis

Because limited reimbursement policies make it difficult for people to receive medical services such as breast tomosynthesis, the market's expansion may be hampered. In developing countries, there are few reimbursement policies for breast tomosynthesis operations. Patients may not be able to afford the expense of this surgery when reimbursement policies are restrictive, which will reduce demand for breast tomosynthesis. This may ultimately result in low rates of technology adoption in underdeveloped nations and slower market expansion. So, government are taking initiatives to provide the maximum reimbursement policies benefits for breast tomosynthesis. During the forecast period, a number of factors, including a lack of public knowledge regarding digital breast tomosynthesis equipment, are anticipated to restrain the market's expansion. For instance, in March 2022, according to an article published in Health Policy journal, the study was to evaluate the association between state DBT coverage mandates and DBT use, prices, and out-of-pocket payments. Although this study focused on the specific case of DBT, insurance coverage mandates are commonly deployed policy strategies intended to improve patient access to a broad range of health services and to protect patients from financial liability.